Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States

Peter D. Feldman, Linda K. Hay, Walter Deberdt, John S. Kennedy, David S. Hutchins, Donald P. Hay, Thomas A. Hardy, Vicki P. Hoffmann, Kenneth Hornbuckle, Alan Breier

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objectives: The objective of this study was to investigate risk of diabetes among elderly patients during treatment with antipsychotic medications. Design: We conducted a longitudinal, retrospective study assessing the incidence of new prescription claims for antihyperglycemic agents during antipsychotic therapy. Setting: Prescription claims from the AdvancePCS claim database were followed for 6 to 9 months. Participants: Study participants consisted of patients in the United States aged 60+ and receiving antipsychotic monotherapy. The following cohorts were studied: an elderly reference population (no antipsychotics: n = 1,836,799), those receiving haloperidol (n = 6481) or thioridazine (n = 1658); all patients receiving any conventional antipsychotic monotherapy (n = 11,546), clozapine (n = 117), olanzapine (n = 5382), quetiapine (n = 1664), and risperidone (n = 12,244), and all patients receiving any atypical antipsychotic monotherapy (n = 19,407). Measurements: We used Cox proportional hazards regression to determine the risk ratio of diabetes for antipsychotic cohorts relative to the reference population. Covariates included sex and exposure duration. Results: New antihyperglycemic prescription rates were higher in each antipsychotic cohort than in the reference population. Overall rates were no different between atypical and conventional antipsychotic cohorts. Among individual antipsychotic cohorts, rates were highest among patients treated with thioridazine (95% confidence interval [CI], 3.1-5.7), lowest with quetiapine (95% CI, 1.3-2.9), and intermediate with haloperidol, olanzapine, and risperidone. Among atypical cohorts, only risperidone users had a significantly higher risk (95% CI, 1.05-1.60; P = 0.016) than for haloperidol. Conclusions about clozapine were hampered by the low number of patients. Conclusion: These data suggest that diabetes risk is elevated among elderly patients receiving antipsychotic treatment. However, causality remains to be demonstrated. As a group, the risk for atypical antipsychotic users was not significantly different than for users of conventional antipsychotics.

Original languageEnglish (US)
Pages (from-to)38-46
Number of pages9
JournalJournal of the American Medical Directors Association
Volume5
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Geriatrics
Antipsychotic Agents
Diabetes Mellitus
Cohort Studies
Retrospective Studies
Population
olanzapine
Risperidone
Therapeutics
Haloperidol
Thioridazine
Prescriptions
Clozapine
Confidence Intervals
Hypoglycemic Agents
Causality
Longitudinal Studies
Odds Ratio
Databases

Keywords

  • Antipsychotics
  • Diabetes mellitus
  • Drug
  • Geriatrics
  • Prescriptions

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. / Feldman, Peter D.; Hay, Linda K.; Deberdt, Walter; Kennedy, John S.; Hutchins, David S.; Hay, Donald P.; Hardy, Thomas A.; Hoffmann, Vicki P.; Hornbuckle, Kenneth; Breier, Alan.

In: Journal of the American Medical Directors Association, Vol. 5, No. 1, 01.2004, p. 38-46.

Research output: Contribution to journalArticle

Feldman, Peter D. ; Hay, Linda K. ; Deberdt, Walter ; Kennedy, John S. ; Hutchins, David S. ; Hay, Donald P. ; Hardy, Thomas A. ; Hoffmann, Vicki P. ; Hornbuckle, Kenneth ; Breier, Alan. / Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. In: Journal of the American Medical Directors Association. 2004 ; Vol. 5, No. 1. pp. 38-46.
@article{6221df51f5a24e24bf54e2265ce38279,
title = "Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States",
abstract = "Objectives: The objective of this study was to investigate risk of diabetes among elderly patients during treatment with antipsychotic medications. Design: We conducted a longitudinal, retrospective study assessing the incidence of new prescription claims for antihyperglycemic agents during antipsychotic therapy. Setting: Prescription claims from the AdvancePCS claim database were followed for 6 to 9 months. Participants: Study participants consisted of patients in the United States aged 60+ and receiving antipsychotic monotherapy. The following cohorts were studied: an elderly reference population (no antipsychotics: n = 1,836,799), those receiving haloperidol (n = 6481) or thioridazine (n = 1658); all patients receiving any conventional antipsychotic monotherapy (n = 11,546), clozapine (n = 117), olanzapine (n = 5382), quetiapine (n = 1664), and risperidone (n = 12,244), and all patients receiving any atypical antipsychotic monotherapy (n = 19,407). Measurements: We used Cox proportional hazards regression to determine the risk ratio of diabetes for antipsychotic cohorts relative to the reference population. Covariates included sex and exposure duration. Results: New antihyperglycemic prescription rates were higher in each antipsychotic cohort than in the reference population. Overall rates were no different between atypical and conventional antipsychotic cohorts. Among individual antipsychotic cohorts, rates were highest among patients treated with thioridazine (95{\%} confidence interval [CI], 3.1-5.7), lowest with quetiapine (95{\%} CI, 1.3-2.9), and intermediate with haloperidol, olanzapine, and risperidone. Among atypical cohorts, only risperidone users had a significantly higher risk (95{\%} CI, 1.05-1.60; P = 0.016) than for haloperidol. Conclusions about clozapine were hampered by the low number of patients. Conclusion: These data suggest that diabetes risk is elevated among elderly patients receiving antipsychotic treatment. However, causality remains to be demonstrated. As a group, the risk for atypical antipsychotic users was not significantly different than for users of conventional antipsychotics.",
keywords = "Antipsychotics, Diabetes mellitus, Drug, Geriatrics, Prescriptions",
author = "Feldman, {Peter D.} and Hay, {Linda K.} and Walter Deberdt and Kennedy, {John S.} and Hutchins, {David S.} and Hay, {Donald P.} and Hardy, {Thomas A.} and Hoffmann, {Vicki P.} and Kenneth Hornbuckle and Alan Breier",
year = "2004",
month = "1",
doi = "10.1016/S1525-8610(04)70042-0",
language = "English (US)",
volume = "5",
pages = "38--46",
journal = "Journal of the American Medical Directors Association",
issn = "1525-8610",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States

AU - Feldman, Peter D.

AU - Hay, Linda K.

AU - Deberdt, Walter

AU - Kennedy, John S.

AU - Hutchins, David S.

AU - Hay, Donald P.

AU - Hardy, Thomas A.

AU - Hoffmann, Vicki P.

AU - Hornbuckle, Kenneth

AU - Breier, Alan

PY - 2004/1

Y1 - 2004/1

N2 - Objectives: The objective of this study was to investigate risk of diabetes among elderly patients during treatment with antipsychotic medications. Design: We conducted a longitudinal, retrospective study assessing the incidence of new prescription claims for antihyperglycemic agents during antipsychotic therapy. Setting: Prescription claims from the AdvancePCS claim database were followed for 6 to 9 months. Participants: Study participants consisted of patients in the United States aged 60+ and receiving antipsychotic monotherapy. The following cohorts were studied: an elderly reference population (no antipsychotics: n = 1,836,799), those receiving haloperidol (n = 6481) or thioridazine (n = 1658); all patients receiving any conventional antipsychotic monotherapy (n = 11,546), clozapine (n = 117), olanzapine (n = 5382), quetiapine (n = 1664), and risperidone (n = 12,244), and all patients receiving any atypical antipsychotic monotherapy (n = 19,407). Measurements: We used Cox proportional hazards regression to determine the risk ratio of diabetes for antipsychotic cohorts relative to the reference population. Covariates included sex and exposure duration. Results: New antihyperglycemic prescription rates were higher in each antipsychotic cohort than in the reference population. Overall rates were no different between atypical and conventional antipsychotic cohorts. Among individual antipsychotic cohorts, rates were highest among patients treated with thioridazine (95% confidence interval [CI], 3.1-5.7), lowest with quetiapine (95% CI, 1.3-2.9), and intermediate with haloperidol, olanzapine, and risperidone. Among atypical cohorts, only risperidone users had a significantly higher risk (95% CI, 1.05-1.60; P = 0.016) than for haloperidol. Conclusions about clozapine were hampered by the low number of patients. Conclusion: These data suggest that diabetes risk is elevated among elderly patients receiving antipsychotic treatment. However, causality remains to be demonstrated. As a group, the risk for atypical antipsychotic users was not significantly different than for users of conventional antipsychotics.

AB - Objectives: The objective of this study was to investigate risk of diabetes among elderly patients during treatment with antipsychotic medications. Design: We conducted a longitudinal, retrospective study assessing the incidence of new prescription claims for antihyperglycemic agents during antipsychotic therapy. Setting: Prescription claims from the AdvancePCS claim database were followed for 6 to 9 months. Participants: Study participants consisted of patients in the United States aged 60+ and receiving antipsychotic monotherapy. The following cohorts were studied: an elderly reference population (no antipsychotics: n = 1,836,799), those receiving haloperidol (n = 6481) or thioridazine (n = 1658); all patients receiving any conventional antipsychotic monotherapy (n = 11,546), clozapine (n = 117), olanzapine (n = 5382), quetiapine (n = 1664), and risperidone (n = 12,244), and all patients receiving any atypical antipsychotic monotherapy (n = 19,407). Measurements: We used Cox proportional hazards regression to determine the risk ratio of diabetes for antipsychotic cohorts relative to the reference population. Covariates included sex and exposure duration. Results: New antihyperglycemic prescription rates were higher in each antipsychotic cohort than in the reference population. Overall rates were no different between atypical and conventional antipsychotic cohorts. Among individual antipsychotic cohorts, rates were highest among patients treated with thioridazine (95% confidence interval [CI], 3.1-5.7), lowest with quetiapine (95% CI, 1.3-2.9), and intermediate with haloperidol, olanzapine, and risperidone. Among atypical cohorts, only risperidone users had a significantly higher risk (95% CI, 1.05-1.60; P = 0.016) than for haloperidol. Conclusions about clozapine were hampered by the low number of patients. Conclusion: These data suggest that diabetes risk is elevated among elderly patients receiving antipsychotic treatment. However, causality remains to be demonstrated. As a group, the risk for atypical antipsychotic users was not significantly different than for users of conventional antipsychotics.

KW - Antipsychotics

KW - Diabetes mellitus

KW - Drug

KW - Geriatrics

KW - Prescriptions

UR - http://www.scopus.com/inward/record.url?scp=9144255372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144255372&partnerID=8YFLogxK

U2 - 10.1016/S1525-8610(04)70042-0

DO - 10.1016/S1525-8610(04)70042-0

M3 - Article

C2 - 14706127

AN - SCOPUS:9144255372

VL - 5

SP - 38

EP - 46

JO - Journal of the American Medical Directors Association

JF - Journal of the American Medical Directors Association

SN - 1525-8610

IS - 1

ER -